Denali Therapeutics Inc. (DNLI)
Sector: Healthcare
Industry: Biological Products, (No Diagnostic Substances)
Country: United States
Exchange: NASDAQ
Market cap: $3.15B
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Latest financial period: June 30, 2026
Filed with the SEC: August 6, 2026
Estimated earnings date: November 5, 2026
Not currently ranked. Cannot calculate: sales growth
Profit Not currently ranked
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROIC | | | | |
Growth Not currently ranked
Payout Not currently ranked
Safety Not currently ranked
Price Not currently ranked
